Reefer MEDness

Trevor Shewfelt and Kirk Nyquist
  • 3.3 (4)
  • Alternative Health
  • Updated Biweekly

As a nurse and pharmacist we focus our stories on people’s use and perception of cannabis as Reefer Madness, Reefer Medicine, Reefer Mellow. We are exploring how society is changing its understanding of cannabis.

  1. E175-2 Cannabis LPs to Veteran Care: Seann Poli & JANrx are Changing Canadian Medical Cannabis - Part 2

    2d ago

    E175-2 Cannabis LPs to Veteran Care: Seann Poli & JANrx are Changing Canadian Medical Cannabis - Part 2

    Can full-spectrum cannabis work better than isolates — even if it tastes worse? In Part 2 with Seann Poli of JAN Rx, Trevor explores CBG, CBC, acidic cannabinoids, the entourage effect, veteran cannabis care, and why cannabis companies are increasingly filling healthcare roles traditionally held by pharmacists and nurses. Plus: a new “rocket fuel” cannabinoid blend, hormone-focused cannabis products, and the future of medical cannabis guidance in Canada. Listen now. Seann Poli - LinkedIn JANrx -Website Transcripts, papers and so much more at: reefermed.ca

    19 min
  2. E175-1 Cannabis LPs to Veteran Care: Seann Poli & JANrx are Changing Canadian Medical Cannabis - Part 1

    May 19

    E175-1 Cannabis LPs to Veteran Care: Seann Poli & JANrx are Changing Canadian Medical Cannabis - Part 1

    Can medical cannabis care become more personalized and patient-focused? Trevor and Kirk talk with Seann Poli of JANrx about raising capital during the early LP boom to building a 100% Canadian, independent medical cannabis company. Seann tells us about veteran cannabis care, challenges dealing with insurance companies, CBD/CBN products, medical cannabis education, and the future of holistic cannabinoid wellness in Canada. Learn how personalized cannabis support is helping veterans manage PTSD, sleep, pain, and overall health for veterans and civilians alike. Seann Poli - LinkedIn JANrx -Website Transcripts, papers and so much more at: reefermed.ca

    21 min
  3. E174-2 Inside Germany’s Cannabis Legalization: How Doctors Prescribe Medical Marijuana with Dr. Vlad Gavril - Part 2

    May 12

    E174-2 Inside Germany’s Cannabis Legalization: How Doctors Prescribe Medical Marijuana with Dr. Vlad Gavril - Part 2

    Tightened Spotify / Apple Podcasts Description Can medical cannabis help patients reduce opioids, sleep better, and reclaim quality of life? In Part 2 of Trevor and Kirk’s conversation with German physician Dr. Vlad Gavril, they continue to explore cannabinoid medicine in Germany. Dr. Vlad discusses chronic pain, insomnia, cannabis smoking vs vaping, opioid reduction, and the evolving German cannabis system. He shares powerful patient stories while emphasizing an honest message: cannabis can help many people — but it’s not magic, and it doesn’t work for everyone. Listen to how cannabis medicine is evolving in Europe. Dr. Vlad Gavril - LinkedIn Transcripts, papers and so much more at: reefermed.ca

    29 min
  4. E174-1 Inside Germany’s Cannabis Legalization: How Doctors Prescribe Medical Marijuana with Dr. Vlad Gavril - Part 1

    May 5

    E174-1 Inside Germany’s Cannabis Legalization: How Doctors Prescribe Medical Marijuana with Dr. Vlad Gavril - Part 1

    A German cannabis physician, a nurse and a pharmacist walk into a bar...I mean a podcast. In this fascinating episode of Reefer MEDness, Trevor (pharmacist) and Kirk (registered nurse) sit down with Dr. Vlad Gavril, a German GP specializing in cannabinoid therapy, to explore how medical cannabis is transforming patient care in Germany. Dr. Vlad explains how Germany’s partial cannabis legalization in April 2024 dramatically changed access to medical cannabis. But with this rapid expansion comes challenges: inconsistent patient education, and stigma around cannabis. The conversation unpacks how Dr. Vlad uses cannabis clinically—from chronic pain and insomnia to depression and ADHD—and why education about cannabinoids, terpenes, and individualized treatment is critical. Dr. Vlad shares how he guides patients toward vaporization rather than smoking, explores terpene-based strain selection, and explains the importance of activating the body’s endocannabinoid system through lifestyle changes alongside cannabis therapy. This episode offers rare insight into the rapidly evolving global landscape of medical cannabis policy, patient care, and cannabinoid science. Listen now to learn how cannabis medicine is being practiced in Germany—and what Canadian clinicians and patients can learn from it. Dr. Vlad Gavril - LinkedIn Transcripts, papers and so much more at: reefermed.ca

    23 min
  5. E173-2 The Future of Cannabis Research: AI, Big Data, and the National Cannabis Registry with Johannes Thrul Part 2

    Apr 28

    E173-2 The Future of Cannabis Research: AI, Big Data, and the National Cannabis Registry with Johannes Thrul Part 2

    Can a massive data project finally answer the biggest questions about medical cannabis? In Part 2 of our conversation with Dr. Johannes Thrul, we explore the National Cannabis Study, an ambitious effort to build a global repository of cannabis research and real-world patient data. From standardized tools like the Cannabis Use Questionnaire to combining datasets from multiple studies, this project aims to uncover how cannabis truly impacts conditions like chronic pain, anxiety, PTSD, and insomnia. With AI analysis, collaborative research, and a goal of 10,000 participants, the team hopes to transform fragmented cannabis studies into one powerful evidence base. Listen now to learn how this groundbreaking cannabis database could reshape the future of cannabis medicine. Johannes Thrul - LinkedIn Cannabis & Health Research Initiative - website Transcripts, papers and so much more at: reefermed.ca

    38 min
  6. E173-1 The Future of Cannabis Research: AI, Big Data, and the National Cannabis Registry with Johannes Thrul Part 1

    Apr 21

    E173-1 The Future of Cannabis Research: AI, Big Data, and the National Cannabis Registry with Johannes Thrul Part 1

    What truth can big data unlock about medical cannabis? Dr. Johannes Thrul from Johns Hopkins talks about cannabis use disorder, psychiatric risks, THC intoxication, and the groundbreaking Cannabis Health Research Initiative. The ambitious Cannabis Health Research Initiative is a groundbreaking effort to build a national medical cannabis registry and research database. Dr. Thrul shares how the National Cannabis Study will track new medical cannabis users over time, analyze biomarkers and electronic health records, and use AI to identify if medicinal cannabis is helping or not. The goal: generate real-world evidence about the benefits, risks, and clinical applications of cannabinoids—helping researchers design better clinical trials and improve patient care. Listen now to learn how real-world data may reshape the science of cannabis medicine. Johannes Thrul - LinkedIn Cannabis & Health Research Initiative - website Transcripts, papers and so much more at: reefermed.ca

  7. E172-2 Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor Part 2

    Apr 14

    E172-2 Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor Part 2

    What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks? In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products. David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors. Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance? Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds. David Traylor - LinkedIn Skunk Works Nature AI - website Transcripts, papers and so much more at: reefermed.ca

    28 min
  8. E172-1 Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor Part 1

    Apr 7

    E172-1 Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor Part 1

    Can big brands explore cannabis, & psychedelics without saying it out loud? What happens when cannabis and natural compounds expertise, a global network, and AI-driven product strategy collide? David Traylor of Golden Eagle Partners introduces Skunk Works Nature AI. This new venture helps major consumer brands quietly explore cannabinoids and other natural compounds. Does a large beverage company want a CBG infused drink to help University Students get over their exam anxiety? Does a Fast-Moving Consumer Goods Brand want a toothpaste with CBN to help people sleep? Does a cosmetics company want a micro-dosed psychedelic lipstick for when an artist or CEO needs some creativity on demand? Large companies may be canna-curious but stigma still slows innovation. The confidential advice and expertise of Skunk Works Nature AI should bring serious players into the space. The future belongs to evidence-based product development built around cannabinoids, alkaloids, terpenes, and other natural compounds. David also discusses the capital crunch in cannabis, why so many firms have exited the sector, and a fascinating discussion about cannabis language and policy, including David’s clearer framework of THC-plus and THC-minus. Listen now to learn how investors, scientists, and global brands are preparing for the next phase of cannabis, psychedelics, and functional natural products.  David Traylor - LinkedIn Skunk Works Nature AI - website Transcripts, papers and so much more at: reefermed.ca

    21 min
See All (228)

Trailer

Ratings & Reviews

3.3
out of 5
4 Ratings

About

As a nurse and pharmacist we focus our stories on people’s use and perception of cannabis as Reefer Madness, Reefer Medicine, Reefer Mellow. We are exploring how society is changing its understanding of cannabis.

Information

  • Creator
    Trevor Shewfelt and Kirk Nyquist
  • Years Active
    2018 - 2026
  • Episodes
    228
  • Rating
    Explicit
  • Copyright
    © Copyright 2026 Reefer MEDness
  • Show Website
    Reefer MEDness

You Might Also Like